The global selective cox-2 inhibitors market outlook study is a comprehensive databook that provides key market data on the global selective cox-2 inhibitors industry. Some of the prominent players in the market are Abbott, Almirall Limited, Apotex, Aurobindo Pharma, Bayer, Boehringer-Ingelheim, Breckenridge Pharmaceutical, Cipla, Geri-Care, Glenmark Pharmaceuticals, Hengrui pharmaceutical, Iroko Pharmaceuticals, Kelun Group, Kopran, Lupin Pharmaceuticals, Meda Pharmaceuticals, Merck, Mylan, Novacap, Perrigo, Pfizer, PuraCap Pharmaceutical, Qilu Pharmaceutical, Takeda, Taro Pharmaceuticals , TerSera Therapeutics, Teva, Yung Shin Pharmaceutical. The research report on the global selective cox-2 inhibitors market provides extensive competition analysis and competitive conditions. The report includes information on significant products, players, challenges and developments, and other information specific to the market.
The purpose of this study is to identify the current market environment for selective cox-2 inhibitors and to assess the market's potential for growth over the forecast period. The research delves into market factors affecting the selective cox-2 inhibitors market (drivers, restraints, opportunities, and trends). The current market for selective cox-2 inhibitors is examined in this report, as well as the market's future trajectory.
The second chapter, market overview, provides an overview of the selective cox-2 inhibitors market. The chapter discusses macroeconomic factors, drivers, restraints, opportunities, challenges, value chain analysis, technology roadmap, and Porter 5 force model analysis.
The global selective cox-2 inhibitors market is extensive, with a detailed description and evaluation of the market. It includes extensive qualitative and quantitative insights into the report that are aligned with our intended customers' goals and objectives.
Attribute | Description |
Base Year | 2022 |
Historical Year | 2019 - 2021 |
Forecast Period | 2023 - 2029 |
Market Value | US$ Million |
Segments Covered |
By Product Type: Meloxicam, Celecoxib, Etoricoxib, Imrecoxib, Etodolac, Parecoxib, Other. By Application: Rheumatoid Arthritis, Osteoarthritis, Spondylosis Chronica Ankylopoietica, Other. |
Geographies Covered |
North America: U.S., Canada Europe: Germany, U.K., France, Italy, Spain, Russia, and the Rest of Europe Asia Pacific: China, India, Japan, Australia, and the Rest of Asia Pacific The Middle East and Africa: GCC, South Africa, and the Rest of Middle East and Africa Latin America: Brazil, Mexico, and the Rest of Latin America |
Companies | Abbott, Almirall Limited, Apotex, Aurobindo Pharma, Bayer, Boehringer-Ingelheim, Breckenridge Pharmaceutical, Cipla, Geri-Care, Glenmark Pharmaceuticals, Hengrui pharmaceutical, Iroko Pharmaceuticals, Kelun Group, Kopran, Lupin Pharmaceuticals, Meda Pharmaceuticals, Merck, Mylan, Novacap, Perrigo, Pfizer, PuraCap Pharmaceutical, Qilu Pharmaceutical, Takeda, Taro Pharmaceuticals , TerSera Therapeutics, Teva, Yung Shin Pharmaceutical |
The global economy is highly affected by COVID-19. Various sectors in the economy are much affected by this pandemic. The global economy will decline because of the loss of trillions of dollars. The growing extension and imposition of lockdown in various countries directly affect the economy all over the world. The report consists of a chapter that provides a detailed study of the impact of COVID-19 on the selective cox-2 inhibitors market. This report is helpful for business and industry practitioners. The study specifically intended to assist in explaining, directing, and understanding the potential of the selective cox-2 inhibitors markets. The study focuses on providing readers with an understanding of developments in the industry. The report also provides detailed insights on market segments, market forecasts, leading players, market drivers, and inhibitors.
Chapter 3, segment analysis provides information on the different sub-segments of the market. The chapter provides an in-depth analysis of the market segments and year-on-year growth projections that enable readers to identify potential market growth areas.
Chapter 4, the regional analysis includes an in-depth analysis of the selective cox-2 inhibitors market by region. The chapter covers several regions, including North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The report also includes a comprehensive analysis of the market by country. The report covers countries such as the United States, Canada, Germany, France, Italy, Spain, China, India, Japan, the GCC, South Africa, Brazil, Mexico, and the rest of the world. Regional insight helps market competitors to make crucial decisions about their company. Individualized, country-wise, and segment-wise analyses by region allow readers to explore the potential of the market in different geographies. This section is a vital part of the report for each year’s growth projections and a global share of value.
Chapter 5, a competitive analysis of the report includes company shares analysis, a list of acquisitions, mergers, collaboration, and the introduction of new products.
Chapter 6, the company profile of the report also covers key industry players working in the selective cox-2 inhibitors market. The report also discusses the business strategies adopted by the players at the global, regional, and country-level. The study also focuses on various businesses or inorganic business development strategies for expanding consumer networks through product formation, organization extension, partnerships, mergers, and acquisitions.
1. Introduction
2. Market Overview
2.1. Global Selective Cox-2 Inhibitors Market Introduction
2.2. Macro- Economic Factor
2.3. Market Determinants
2.3.1. Market Driver
2.3.2. Market Restraints
2.3.3. Market Opportunities
2.3.4. Market Challenges
2.4. Technology/Product Roadmap
2.5. PEST Analysis
2.6. Market Growth Opportunity Analysis
2.7. Impact of Covid-19 on Selective Cox-2 Inhibitors Market
3. Market Segmentation
3.1. Global Selective Cox-2 Inhibitors Market Analysis (US$ Mn), By Product Type, 2019 - 2029
3.1.1 Meloxicam
3.1.2 Celecoxib
3.1.3 Etoricoxib
3.1.4 Imrecoxib
3.1.5 Etodolac
3.1.6 Parecoxib
3.1.7 Other
3.2. Global Selective Cox-2 Inhibitors Market Analysis (US$ Mn), By Application, 2019 - 2029
3.2.1 Rheumatoid Arthritis
3.2.2 Osteoarthritis
3.2.3 Spondylosis Chronica Ankylopoietica
3.2.4 Other
4. Regional Analysis
4.1. North America Selective Cox-2 Inhibitors Market Analysis (US$ Mn), 2019 - 2029
4.1.1. By Country
4.1.1.1. U.S.
4.1.1.2.Canada
4.1.2.By Product Type
4.1.3.By Application
4.2.Europe Selective Cox-2 Inhibitors Market Analysis (US$ Mn), 2019 - 2029
4.2.1.By Country
4.2.1.1.Germany
4.2.1.2.U.K.
4.2.1.3.France
4.2.1.4.Italy
4.2.1.5.Spain
4.2.1.6.Rest of Europe
4.2.2.By Product Type
4.2.3.By Application
4.3.Asia Pacific Selective Cox-2 Inhibitors Market Analysis (US$ Mn), 2019 - 2029
4.3.1.By Country
4.3.1.1.China
4.3.1.2.Japan
4.3.1.3.India
4.3.1.4.Rest of Asia Pacific
4.3.2.By Product Type
4.3.3.By Application
4.4.Rest of world Selective Cox-2 Inhibitors Market Analysis (US$ Mn), 2019 - 2029
4.4.1. By Region
4.4.1.1. Middle East & Africa
4.4.1.2. Latin America
4.4.2.By Product Type
4.4.3. By Application
5.Company Profiles
5.1 Abbott
5.2 Almirall Limited
5.3 Apotex
5.4 Aurobindo Pharma
5.5 Bayer
5.6 Boehringer-Ingelheim
5.7 Breckenridge Pharmaceutical
5.8 Cipla
5.9 Geri-Care
5.10 Glenmark Pharmaceuticals
5.11 Hengrui pharmaceutical
5.12 Iroko Pharmaceuticals
5.13 Kelun Group
5.14 Kopran
5.15 Lupin Pharmaceuticals
5.16 Meda Pharmaceuticals
5.17 Merck
5.18 Mylan
5.19 Novacap
5.20 Perrigo
5.21 Pfizer
5.22 PuraCap Pharmaceutical
5.23 Qilu Pharmaceutical
5.24 Takeda
5.25 Taro PharmaceuticalsÂ
5.26 TerSera Therapeutics
5.27 Teva
5.28 Yung Shin Pharmaceutical